|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Treating comorbid anxiety and depression: Psychosocial and pharmacological approaches显示文摘Comorbid anxiety with depression predicts poor outcomes with a higher percentage of treatment resistance than either disorder occurring alone. Overlap of anxiety and depression complicates diagnosis and renders treatment challenging. A vital step in treatment of such comorbidity is careful and comprehensive diagnostic assessment. We attempt to explain various psychosocial and pharmacological approaches for treatment of comorbid anxiety and depression. For the psychosocial component, we focus only on generalized anxiety disorder based on the following theoretical models:(1) 'the avoidance model';(2) 'the intolerance of uncertainty model';(3) 'the meta-cognitive model';(4) 'the emotion dysregulation model'; and(5) 'the acceptance based model'. For depression, the following theoretical models are explicated:(1) 'the cognitive model';(2) 'the behavioral activation model'; and(3) 'the interpersonal model'. Integration of these approaches is suggested. The treatment of comorbid anxiety and depression necessitates specific psychopharmacological adjustments as compared to treating either condition alone. Serotonin reuptake inhibitors are considered first-line treatment in uncomplicated depression comorbid with a spectrum of anxiety disorders. Short-acting benzodiazepines(BZDs) are an important 'bridging strategy' to address an acute anxiety component. In patients with comorbid substance abuse, avoidance of BZDs is recommended and we advise using an atypical antipsychotic in lieu of BZDs. For mixed anxiety and depression comorbid with bipolar disorder, we recommend augmentation of an antidepressant with either lamotrigine or an atypical agent. Combination and augmentation therapies in the treatment of comorbid conditions vis-à-vis monotherapy may be necessary for positive outcomes. Combination therapy with tricyclic antidepressants, gabapentin and selective serotonin/norepinephrine reuptake inhibitors(e.g., duloxetine) are specifically useful for comorbid chronic pain syndromes. Aripiprazole, quetiapine, risperidone and other novel atypical agents may be effective as augmentations. For treatment-resistant patients, we recommend a 'stacking approach' not dissimilar from treatment of hypertension In conclusion, we delineate a comprehensive approach comprising integration of various psychosocial approaches and incremental pharmacological interventions entailing bridging strategies, augmentation therapies and ultimately stacking approaches towards effectively treating comorbid anxiety and depression. | Jeremy D Coplan Cindy J Aaronson Venkatesh Panthangi Younsuk Kim | 2015 | World Journal of Psychiatry2015，5，4： | 7 |
| 2 | The Clinical Meaning of Rankin `Handicap’ Grades After Stroke显示文摘 | R. de Haan M. Limburg P. Bossuyt J. van der Meulen N. Aaronson | 1995 | Stroke A Journal of Cerebral Circulation1995，，11： | 2 |
| 3 | The Formation of Proeutectoid Ferrite in Carbon Steels 显示文摘 | Dube C A Aaronson H I Mehl R F | 1958 | Rev Met1958，55，3： | 1 |
| 4 | Growth Kinetics of Grain Boundary Ferrite Allotriomorphs in Fe-C Alloys 显示文摘 | Bradley J R Rigsbee J M Aaronson H I | 1977 | Metall Trans1977，8，2： | 1 |
| 5 | The European Organization for Research and Treatment of Cancer QLQ - c30: a quality - of - life instrument for use in international clinical trials in oncology 显示文摘 | Aaronson NK Ahmedzai S Bergman B | 1993 | J Natl Cancer Inst1993，85，5： | 1 |
| 6 | Growth Kinetics of Grain Boundary Ferrite Allotriomorphs in Fe-C-X Alloys 显示文摘 | Bradley J R Aaronson H I | 1981 | Metall Trans1981，12，10： | 1 |
| 7 | The European or- ganization for research and treatment of cancer QLQ-C30: A quali- ty of life instrument for use in international clinical trials in oncology 显示文摘 | Aaronson N K Ahmedzai S Bergman B | 1993 | Journal of the National Cancer Institute1993，85，5： | 1 |
| 8 | Randomized phase Ⅲ study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma显示文摘 | Middleton MR Grob J J Aaronson N | 2000 | J Clin Oncol2000，18，： | 1 |
| 9 | The European organization for research and treatment of cancer QLQ- C30 : A quality - of - life instrument for sue in international clinical trials in oncology显示文摘 | Aaronson NK Ahmedzai S Bergman B | 1993 | J Natl Cancer Inst1993，85，： | 1 |
| 10 | Lectures on the Theory of Phase Transformation显示文摘 | Lee J K | 1975 | H I Aaronson1975，，： | 1 |
| 11 | Influence of Al, Co, and Si Upon the Kinetics of the Proentectoid Ferrite Reaction 显示文摘 | Kinsman K R Aaronson H I | 1973 | Metall Trans1973，4959，： | 1 |
| 12 | preeatment quality of life of inoperable non-small cell lung cancer patients referred for primary radiotherapy显示文摘 | Langendijk JA Zvunl Aaronson NK | 2000 | Acta Oncologica2000，39，： | 1 |
| 13 | Growth and Overall Transformation Kinetics above Bay Temperature in Fe-C-Mo alloys 显示文摘 | Shifter G J Aaronson H I | 1990 | Metall Trans1990，21，12： | 1 |
| 14 | The EORTC modular ap- proach to quality of life assessment in oneology显示文摘 | Aaronson N K Cull A Kaasa S | 1994 | International Journal of Mental Health nursing1994，23，4： | 1 |
| 15 | A road map for those who don't know JAK-STAT显示文摘 | Aaronson D S Horvath C M | 2002 | Science2002，296，5573： | 1 |
| 16 | Cell redox state and hypoxic pulmo- nary vasoconstriction :recent evidence and possible mechanisms 显示文摘 | Connolly MJ Aaronson PI | 2010 | Respir Physiol Neurobiol2010，174，3： | 1 |
| 17 | The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates显示文摘 | Matthews JC Koelling TM Pagani D Aaronson KD | 2008 | J Am Coll Cardiol2008，51，： | 1 |
| 18 | The European Organization for Research and Treatment of Cancer QLQC30: a quality of life instrument for use in international clinical trials in oncology显示文摘 | Aaronson NK Ahmedzai S Bergman B | 1993 | J Natl Cancer Inst1993，85，5： | 1 |
| 19 | Growth of Grain Boundary Precipitates in Al-4% Cu By Interracial Diffusion 显示文摘 | Aaron H B Aaronson H I | 1968 | Acta Metall1968，16，6： | 1 |
| 20 | Defining and measuring fatigue显示文摘 | Aaronson L Teel C Cassmeyer V | 1999 | Image J Nurs Sch1999，31，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员